Repository logo
 

Publication:
In vivo study of hypericin-loaded poloxamer-based mucoadhesive in situ gelling liquid crystalline precursor system in a mice model of vulvovaginal candidiasis

dc.contributor.authorDe Araújo, Patricia Rocha [UNESP]
dc.contributor.authorCalixto, Giovana Maria Fioramonti [UNESP]
dc.contributor.authorAraújo, Victor Hugo Sousa [UNESP]
dc.contributor.authorSato, Mariana Rillo [UNESP]
dc.contributor.authorRodero, Camila Fernanda [UNESP]
dc.contributor.authorOshiro-Junior, João Augusto
dc.contributor.authorBauab, Taís Maria [UNESP]
dc.contributor.authorChorilli, Marlus [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionCampina Grande
dc.date.accessioned2022-05-01T08:44:42Z
dc.date.available2022-05-01T08:44:42Z
dc.date.issued2021-08-01
dc.description.abstractThe present study reports the performance of the pigment hypericin (HYP)-loaded poloxamer-based mucoadhesive in situ gelling liquid crystalline precursor system (LCPS) for the treatment of vulvovaginal candidiasis (VVC) in mice. LCPS composed of 40% of ethoxylated and propoxylated cetyl alcohol, 30% of oleic acid and cholesterol (7:1), 30% of a dispersion of 16% poloxamer 407 and 0.05% of HYP (HYP-LCPS) was prepared and characterized by polarized light microscopy (PLM), small-angle X-ray scattering (SAXS) and ex vivo permeation and retention studies across vaginal porcine mucosa were performed. In addition, the antifungal properties of the HYP-LCPS were evaluated in a murine in vivo model; for this, infected C57BL female mice groups were treated with both HYP in solution and HYP-LCPS, and after 6 days colony forming unit (CFU)/ml count was performed. PLM and SAXS confirmed that HYP-LCPS is a microemulsion situated in boundary transition region confirming its action as an LCPS. When in contact with simulated vaginal fluid, HYP-LCPS became rigid and exhibited maltase crosses and bragg peaks characteristics of lamellar phase. Ex vivo permeation and retention studies showed that HYP-LCPS provides a localized treatment on the superficial layers of porcine vaginal mucosa. HYP-LCPS induced a significant reduction in the number of CFU/ml in the mice; thus this formulation indicated it is as effective as a commercial dosage form. It was concluded that LCPS maintains the biological activity of HYP and provides an adequate drug delivery system for this lipophilic molecule at the vaginal mucosa, being a promising option in cases of VVC.en
dc.description.affiliationSão Paulo State University (UNESP) School of Pharmaceutical Sciences, Araraquara
dc.description.affiliationDepartment of Biosciences Piracicaba Dental School University of Campinas - UNICAMP, Piracicaba
dc.description.affiliationParaíba State University Campina Grande
dc.description.affiliationUnespSão Paulo State University (UNESP) School of Pharmaceutical Sciences, Araraquara
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIdFAPESP: 16/11198-4
dc.description.sponsorshipIdFAPESP: 2019/10261-2
dc.format.extent821-827
dc.identifierhttp://dx.doi.org/10.1093/mmy/myab006
dc.identifier.citationMedical Mycology, v. 59, n. 8, p. 821-827, 2021.
dc.identifier.doi10.1093/mmy/myab006
dc.identifier.issn1460-2709
dc.identifier.issn1369-3786
dc.identifier.scopus2-s2.0-85113765864
dc.identifier.urihttp://hdl.handle.net/11449/233444
dc.language.isoeng
dc.relation.ispartofMedical Mycology
dc.sourceScopus
dc.subjecthypericin
dc.subjectliquid crystalline system
dc.subjectmurine model
dc.subjectvulvovaginal candidiasis
dc.titleIn vivo study of hypericin-loaded poloxamer-based mucoadhesive in situ gelling liquid crystalline precursor system in a mice model of vulvovaginal candidiasisen
dc.typeArtigopt
dspace.entity.typePublication
relation.isDepartmentOfPublication5004bcab-94af-4939-b980-091ae9d0a19e
relation.isDepartmentOfPublicatione214da1b-9929-4ae9-b8fd-655e9bfeda4b
relation.isDepartmentOfPublication.latestForDiscovery5004bcab-94af-4939-b980-091ae9d0a19e
unesp.author.orcid0000-0003-1041-5835 0000-0003-1041-5835[2]
unesp.author.orcid0000-0002-6698-0545[8]
unesp.departmentCiências Biológicas - FCFpt
unesp.departmentFármacos e Medicamentos - FCFpt

Files